• Hwail Pharm issued a correction Nov. 5, 2026, finalizing proposals for its Nov. 20 extraordinary shareholders meeting.
• Proposed charter amendments would add semiconductor, artificial intelligence and hospitality businesses, among other activities.
• Shareholders will vote on appointing two internal directors, two independent directors and one full-time auditor, each for three-year terms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hwail Pharm Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261105900796), on November 05, 2026, and is solely responsible for the information contained therein.